These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 25986689)

  • 41. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
    Qin H; Shi J; Noberini R; Pasquale EB; Song J
    J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques.
    Di Lello P; Pastor R; Murray JM; Blake RA; Cohen F; Crawford TD; Drobnick J; Drummond J; Kategaya L; Kleinheinz T; Maurer T; Rougé L; Zhao X; Wertz I; Ndubaku C; Tsui V
    J Med Chem; 2017 Dec; 60(24):10056-10070. PubMed ID: 29166018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fragment screening using X-ray crystallography.
    Davies TG; Tickle IJ
    Top Curr Chem; 2012; 317():33-59. PubMed ID: 21678136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-Throughput Screening (HTS) by NMR Guided Identification of Novel Agents Targeting the Protein Docking Domain of YopH.
    Bottini A; Wu B; Barile E; De SK; Leone M; Pellecchia M
    ChemMedChem; 2016 Apr; 11(8):919-27. PubMed ID: 26592695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
    Silvestre HL; Blundell TL; Abell C; Ciulli A
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
    Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
    Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
    J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
    Draxler SW; Bauer M; Eickmeier C; Nadal S; Nar H; Rangel Rojas D; Seeliger D; Zeeb M; Fiegen D
    J Med Chem; 2020 Jun; 63(11):5856-5864. PubMed ID: 32420743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery.
    Linke P; Amaning K; Maschberger M; Vallee F; Steier V; Baaske P; Duhr S; Breitsprecher D; Rak A
    J Biomol Screen; 2016 Apr; 21(4):414-21. PubMed ID: 26637553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NMR fragment screening: tackling protein-protein interaction targets.
    Schade M; Oschkinat H
    Curr Opin Drug Discov Devel; 2005 May; 8(3):365-73. PubMed ID: 15892252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fragment-based drug discovery-the importance of high-quality molecule libraries.
    Bon M; Bilsland A; Bower J; McAulay K
    Mol Oncol; 2022 Nov; 16(21):3761-3777. PubMed ID: 35749608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.
    Petros AM; Swann SL; Song D; Swinger K; Park C; Zhang H; Wendt MD; Kunzer AR; Souers AJ; Sun C
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1484-8. PubMed ID: 24582986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integration of NMR and high-throughput screening.
    Hajduk PJ; Burns DJ
    Comb Chem High Throughput Screen; 2002 Dec; 5(8):613-21. PubMed ID: 12470258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving small molecule virtual screening strategies for the next generation of therapeutics.
    Wingert BM; Camacho CJ
    Curr Opin Chem Biol; 2018 Jun; 44():87-92. PubMed ID: 29920436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of potent inhibitors by fragment-linking strategies.
    Bedwell EV; McCarthy WJ; Coyne AG; Abell C
    Chem Biol Drug Des; 2022 Oct; 100(4):469-486. PubMed ID: 35854428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Applications of Biophysics in High-Throughput Screening Hit Validation.
    Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
    J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.